NLX-112, a Selective 5‑HT1A Receptor Agonist, Upregulates GDNF and is Neuroprotective Against MPTP-Induced Nigrostriatal Degeneration in a Mouse Model of Parkinson’s Disease
William H. Powell, Lucy E. Annett, Ronan Depoortere, Adrian Newman-Tancredi, Mahmoud M. Iravani · 2026
Read NLX-112, a Selective 5‑HT1A Receptor Agonist, Upregulates GDNF and is Neuroprotective Against MPTP-Induced Nigrostriatal Degeneration in a Mouse Model of Parkinson’s Disease by William H. Powell, Lucy E. Annett, Ronan Depoortere, Adrian Newman-Tancredi, Mahmoud M. Iravani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13543656.txt.
Description
William Powell and four co-authors wrote a 2026 study testing whether a serotonin-targeting drug protects the brain in a mouse model of Parkinson's disease. The drug, NLX-112, activates the 5-HT1A receptor and already passed a mid-stage trial against involuntary movements caused by Parkinson's treatment. Protection of neurons would be a bigger prize.
Mice received the toxin MPTP, which kills dopamine neurons, with or without daily drug for fifteen days. MPTP alone cut dopamine neurons in the substantia nigra by 40 percent and nerve terminals in the striatum by 55 percent. The drug completely prevented the neuron loss and softened terminal loss to 30 percent. Treated mice also moved more and showed less anxiety-like behavior weeks later. The drug raised GDNF, a growth factor, in line with protection.
Catalog record
| CREATOR | William H. Powell, Lucy E. Annett, Ronan Depoortere, Adrian Newman-Tancredi, Mahmoud M. Iravani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |